Standout Papers
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015)
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes (2016)
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes (2019)
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease (2017)
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial (2017)
Immediate Impact
1 from Science/Nature 66 standout
Citing Papers
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2025 Standout
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
2022 Standout
Works of Michaela Mattheus being referenced
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
2024
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Michaela Mattheus | 11062 | 4754 | 4439 | 80 | 13.1k | |
| Odd Erik Johansen | 14296 | 6166 | 5659 | 118 | 17.1k | |
| Stefan Hantel | 9082 | 4555 | 3893 | 62 | 13.3k | |
| Ofri Mosenzon | 12734 | 4655 | 5245 | 140 | 15.1k | |
| Hans J. Woerle | 11126 | 5444 | 5008 | 88 | 12.9k | |
| Maximilian von Eynatten | 7968 | 3409 | 3119 | 114 | 10.7k | |
| Mehul Desai | 7621 | 3333 | 3202 | 49 | 9.2k | |
| Greg Fulcher | 7548 | 3312 | 2847 | 62 | 9.2k | |
| David Fitchett | 12416 | 6610 | 5125 | 198 | 18.0k | |
| Avivit Cahn | 7371 | 2872 | 3007 | 111 | 8.8k | |
| David Z.I. Cherney | 10214 | 4801 | 3528 | 323 | 14.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...